

Active Research Studies at Corewell Health West

3/29/2024

Neurology

Epilepsy

XEN1101 Focal Onset

Phase 3, randomized, double-blind, placebo-controlled, multicenter drug study

RD2022-0122 NAUTILUS

NCT05147571

RNS® System Responsive Thalamic Stimulation for Primary Generalized Seizures Study (NAUTILUS Study)

Neurodegenerative

Trehalose Injection for ALS

Expanded Access Protocol of Intravenous Trehalose Injection 90.5mg/mL Treatment of Patients with ALS

Healey ALS

Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS

Neurosurgery

Impact of BDNF Variants on Deep Brain Stimulation outcomes

TRAC - This study is designed to assess the safety and effectiveness of the ThrombX Retriever in revascularizing the site of primary occlusion in patients presenting with acute ischemic stroke secondary to intracranial, large vessel, occlusive disease

Neurovascular

Distal Ischemic Stroke Treatment with Adjustable Low-profile Stentriever (DISTALS Study)

The objective of the randomized DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in subjects presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.

CITADEL-T

A prospective, multicenter, single-arm, non-randomized clinical study designed to evaluate the safety and effectiveness of the Citadel Embolization Device.

Stroke

For information about research studies listed please use these contacts below:

Email: researchassist@corewellhealth.org

Phone: 616-391-3050

VERIFY *Validation of early prognostic data for recovery outcome after stroke for future, higher yield trials*

RP2021-0488 Genentech HASTe *Increase stroke awareness among the at-risk population as defined by validated risk score. Stroke awareness will significantly increase following the implementation of stroke risk intervention program(s) of this project, in regional communities.*

EMBOLISE
NCT04402632 *Embolization of the Middle Meningeal Artery with ONYXTM Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE)*

RAGE *Second-generation hydrogel coils (HydroFrame®, HydroFill®, HydroSoft®, HydroSoft® 3D) used in any combination comprising a minimum of 90% total coil length used. Future hydrogel coils approved by the FDA (or applicable regulatory body) may also be included upon availability. Objective To determine occlusion rates and safety when hydrogel coils are used in the treatment of ruptured intracranial aneurysms.*

For information about research studies listed please use these contacts below:

Email: researchassist@corewellhealth.org

Phone: 616-391-3050